Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Halozyme to $55 from $65 and keeps an Overweight rating on the shares. Despite EU co-formulation patent setback, the firm thinks the company can still achieve $1B+ 2027 royalties and grow through 2030. Long term, co-formulation IP is important, and Wells sees value from protection of PD(L)1s & CD20 pipeline.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HALO:
- Halozyme reaffirms FY23 revenue view $815M-$845M, consensus $829.01M
- Halozyme provides update on EPO decision regarding Darzalex
- Halozyme director Henderson sells 20,000 common shares
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
- Halozyme sees FY23 adjusted EPS $2.50-$2.65, consensus $2.78
